Ingevity Corporation reported $1.16B of revenue over the trailing twelve months, −1.4% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.16B (to Q2 2026). Net income: $54M, trailing twelve months to Q2 2026. Free cash flow: $155M, trailing twelve months to Q2 2026. EPS: $1.50, trailing twelve months to Q2 2026.

NGVTIngevity Corporation

Basic Materials

$69.86+24% 1Y

$69.86

$46.2052 weeks$77.87

NGVT as reported

Ingevity Corporation reported $1.16B of revenue over the trailing twelve months, −1.4% on the year before. 11 reported series are charted on this page, each one as filed.

$1.16B

Revenue, trailing twelve months · to Q2 2026 · −1.4% against the twelve months before

Net income: $54M
Net income · −125% year on year · trailing twelve months to Q2 2026
Free cash flow: $155M
Free cash flow · +3.1% year on year · trailing twelve months to Q2 2026
EPS: $1.50
EPS · −125% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for NGVT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.16B	−1.4%	Q2 2026
Net income	$54M	−125%	Q2 2026
EPS	$1.50	−125%	Q2 2026
Gross margin	41%	n/a	Q2 2026
Operating margin	33%	n/a	Q4 2024 · 6 quarters behind
Net margin	3.6%	n/a	Q2 2026
ROE	−206%	n/a	Q2 2026
ROA	−4.5%	n/a	Q2 2026
ROIC	19%	n/a	Q4 2024 · 6 quarters behind
Free cash flow	$155M	+3.1%	Q2 2026
P/E	46.6	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.